GlucoTrack Gestione

Criteri Gestione verificati 0/4

GlucoTrack Il CEO è Erik Emerson, nominato in Jul2026, ha un mandato di meno di un anno. possiede direttamente 0.002% delle azioni della società, per un valore di $ 39.54. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.4 anni e 1.9 anni.

Informazioni chiave

Erik Emerson

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.002%
Durata media del management	1.4yrs
Durata media del Consiglio di amministrazione	1.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Oct 10

GlucoTrack to start R&D program for glucose monitoring system

GlucoTrack (NASDAQ:GCTK) said it will begin a new R&D program for a long-term continuous glucose monitor to expand its product pipeline. Following a recent acquisition of certain related IP, GlucoTrack intends to develop a long-term implantable glucose management technology to address the Type 1 diabetes market, the company said in an Oct. 10 press release. GlucoTrack said it previously reported that it completed lab testing of its non-invasive GlucoTrack 2.0 clinical prototype system and saw better-than-expected accuracy and performance with the technology. The company is scheduled to begin its first-in-human trials later this quarter.

AMMINISTRATORE DELEGATO

Erik Emerson (55 yo)

less than a year

Mandato

Mr. Erik C. Emerson is CEO & Director of Lokahi Therapeutics Inc. Mr. Emerson is Chief Executive Officer & Director of GlucoTrack, Inc. from July 14, 2026. Mr. Emerson was appointed Chief Executive Officer...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Goode	Chief Technical Officer	less than a year	US$394.10k	0.0054% $ 115.9
Erik Emerson	CEO & Director	less than a year	Nessun dato	0.0019% $ 39.5
Avner Gal	Co-Founder	25.6yrs	US$187.39k	Nessun dato
David Malka	Co-Founder	25.6yrs	US$199.35k	Nessun dato
Vincent Wong	Chief Operations Officer	1.4yrs	Nessun dato	0.000020% $ 0.4
Mark Tapsak	Chief Scientific Officer	1.4yrs	US$176.21k	Nessun dato
Drinda Benjamin	Chief Commercial Officer	less than a year	Nessun dato	Nessun dato

1.4yrs

Durata media

57.5yo

Età media

Gestione esperta: Il team dirigenziale di GCTK non è considerato esperto (durata media 1.4 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Goode	Chief Technical Officer	1.9yrs	US$394.10k	0.0054% $ 115.9
Erik Emerson	CEO & Director	less than a year	Nessun dato	0.0019% $ 39.5
Avner Gal	Co-Founder	9.4yrs	US$187.39k	Nessun dato
Andrew Balo	Independent Director	2.2yrs	US$114.00k	0.075% $ 1.6k
Luis Malave	Independent Chairman	5.2yrs	US$134.00k	0.065% $ 1.4k
David Klonoff	Chair of Scientific Advisory Board	5.3yrs	Nessun dato	Nessun dato
Erin Carter	Independent Director	3yrs	US$114.00k	0.034% $ 733.6
Victoria Carr-Brendel	Independent Director	1.3yrs	US$74.83k	0.0069% $ 148.1
Guillermo Umpierrez	Chair of Medical Advisory Board	1.5yrs	Nessun dato	Nessun dato
Usman Latif	Member of Clinical Advisory Board	less than a year	Nessun dato	Nessun dato
David Hirsh	Clinical & Scientific Advisor	1yr	Nessun dato	Nessun dato

1.9yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di GCTK non è considerato esperto (durata media del mandato 1.9 anni), il che suggerisce un nuovo consiglio.

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/08/21 17:25
Prezzo dell'azione a fine giornata	2026/08/20 00:00
Utili	2026/06/30
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

GlucoTrack, Inc. è coperta da 0 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

GlucoTrack Gestione

Criteri Gestione verificati 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

GlucoTrack, Inc., Annual General Meeting, Aug 18, 2026

Glucotrack, Inc. and Lokahi Therapeutics Announces Executive Appointments to Its Combined Company

High number of new and inexperienced directors

Glucotrack, Inc. Appoints Usman Latif to its Clinical Advisory Team

Glucotrack, Inc. Appoints David S. Hirsh, MD as Medical Director, Cardiology

Glucotrack, Inc. Approves the Election of Victoria Carr-Brendel as Director

Recent updates

Glucotrack, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement

GlucoTrack, Inc. announced that it expects to receive $5.5 million in funding

GlucoTrack, Inc., Annual General Meeting, Aug 18, 2026

Lokahi Therapeutics Inc. entered into an Agreement and Plan of Merger to acquire GlucoTrack, Inc. (NasdaqCM:GCTK) in a reverse merger transaction.

Glucotrack, Inc. and Lokahi Therapeutics Announces Executive Appointments to Its Combined Company

Glucotrack Inc Highlights Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association 2026 Scientific Sessions

New major risk - Negative shareholders equity

Glucotrack, Inc. Receives Nasdaq Notice for Failure to Comply with the Minimum Stockholders’ Equity Requirement

Glucotrack Inc Announces Peer-Reviewed Study Supporting Long-Life Sensor Design For Implantable Continuous Blood Glucose Monitoring Technology

High number of new and inexperienced directors

New major risk - Financial position

Glucotrack Inc Files Significant Ide with Fda for Us Clinical Trial in Early Second Quarter Based on Critical 2025 Milestones

New major risk - Share price stability

GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $3.999997 million.

New major risk - Financial position

Glucotrack, Inc. Appoints Usman Latif to its Clinical Advisory Team

GlucoTrack, Inc. announced that it has received $3 million in funding

GlucoTrack, Inc. announced that it expects to receive $20 million in funding from Sixth Borough Capital Management, LP.

Glucotrack, Inc. Appoints David S. Hirsh, MD as Medical Director, Cardiology

Glucotrack, Inc. and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor At American Diabetes Association's 85Th Scientific Sessions

Glucotrack, Inc. Approves the Election of Victoria Carr-Brendel as Director

New major risk - Financial position

Glucotrack, Inc. Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor

GlucoTrack, Inc., Annual General Meeting, May 22, 2025

Nasdaq Determines to Delist GlucoTrack Securities Due to Non-Compliance with Bid Price Rule

Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member

GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $3.033748 million.

Glucotrack, Inc. Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor

GlucoTrack Announces Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Price Requirement

GlucoTrack, Inc. Announces Chief Financial Officer Changes

GlucoTrack, Inc. Receives Nasdaq Non-Compliance Letter Regarding Bid Price Rule

GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $8.23 million.

GlucoTrack, Inc. Announces Start of Enrollment for Human Clinical Study of Continuous Blood Glucose Monitor

GlucoTrack, Inc. has completed a Follow-on Equity Offering in the amount of $9.995237 million.

Glucotrack, Inc. Appoints John Ballantyne to Its Board of Directors

GlucoTrack, Inc. announced that it has received $0.1 million in funding

Glucotrack Announces the Appointment of Andy Balo to Board of Directors

Glucotrack Reports Successful Completion of First Reported Long-Term Preclinical Study of Its Epidural Glucose Monitoring Sensor

Glucotrack, Inc Announces 90-Day Preclinical Study Results That Demonstrate Sustained Accuracy of Its Implantable Continuous Blood Glucose Monitor

GlucoTrack Receives a Third Letter from Nasdaq Notifies Not Regains Compliance with the Minimum Bid Price Requirement During the Extended Compliance Period

Glucotrack’s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study

Glucotrack Announces Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Requirement

GlucoTrack, Inc. announced that it has received $0.5 million in funding

GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose Monitoring

Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose Monitor

GlucoTrack, Inc., Annual General Meeting, Apr 26, 2024

Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors

GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose Monitor

GlucoTrack, Inc. Announces Executive Changes

Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee

Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose Monitor

GlucoTrack Receives Letter from Nasdaq Regarding No Longer Complies with Nasdaq's Listing Rule 5550(a)(2)

Nasdaq Issues a Letter to GlucoTrack Granting an Extension Until May 22, 2023 to Obtain Compliance

Glucotrack to Begin Research & Development of Novel Continuous Glucose Monitoring System

GlucoTrack to start R&D program for glucose monitoring system

GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor

Shalom Shushan, Chief Technology Officer, Provides Notice of His Resignation from Glucotrack, Inc., Effective May 22, 2022

Integrity Applications, Inc. announced delayed 10-Q filing

Integrity Applications, Inc. announced delayed annual 10-K filing

Integrity Applications, Inc. Announces Executive Changes

Integrity Applications Appoints Paul V. Goode to Board of Directors

Integrity Applications, Inc. Appoints Shalom Shushan as Chief Technology Officer, Effective November 9, 2020

Integrity Applications, Inc. Announces Resignation of Eugene Naidis as Vice President of R&D, Effective December 31, 2020

AMMINISTRATORE DELEGATO

Gruppo dirigente

Membri del Consiglio di amministrazione

Analisi aziendale e situazione dei dati finanziari

Fonti dei dati

Modello di analisi e Snowflake